Phase 3 N=204 Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries
Acute Blunt Soft Tissue Injuries/Contusions
Primary: Pain on Movement — 33.1; 65.4 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=267 BEFAST (Bubble-Enhanced FAST) for the Evaluation of Solid Organ Injury
Abdominal Trauma
Primary: Sensitivity of Detecting Solid Organ Injury Measured as the Number of True Positives — 18; 20 Participants
N/A N=249 Vacuum Assisted Closure as a Treatment for Soft Tissue Injuries
Fracture of Calcaneus, Pilon or Tibial Plateau
Primary: Healing of Orthopaedic Trauma Extremity Wound Fractures (Calcaneus, Pilon and Tibial Plateau) — 99; 127 Fractures
N/A N=20 Endovascular Repair for the Descending Thoracic Aorta
Aorta Thoracic; Traumatic Rupture
Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events
Phase 2 N=100 Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma
Blunt Chest Wall Trauma · Rib Fracture · Sternal Fracture
Primary: Opioid Requirement at 24 Hours Post-randomization — 38; 202 morphine milligram equivalents
N/A N=1,051 Shock, Whole Blood, and Assessment of TBI S.W.A.T. (LITES TO 2)
Hemorrhagic Shock · Traumatic Brain Injury
Primary: 4 Hour Mortality — 50; 32 Participants
Phase 2 N=76 A Clinical Trial to Compare Safety and Effectiveness for Relieving Tenderness of 10% Naproxen Gel vs. a 2.32% Diclofenac Diethylamine Gel in the Treatment of Strains and Bruises of the Legs.
Soft Tissue Injury
Primary: Tenderness (Algometry) Over the Initial 72 Hours — 1213.88; 1041.04; 850.79 Nxh/cm^2 — p=0.0221
Phase 2 N=200 Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain
Soft Tissue Injuries · Contusions · Strains
Primary: Change of Pain-on-movement (POM) Compared to Baseline — -50.7; -21.6 units on a scale — p=< 0.0001
N/A N=10 RF/PEMF Versus Ultrasound for the Treatment of Soft Tissue Injury
Soft Tissue Injuries
Primary: Mean Reduction in BPI-SF Severity — 2.75; 2.44 score on a scale
N/A N=5 Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy
Hemorrhagic Shock
Primary: Biological Response as Characterized by Selected Cytokines, Specifically Tumor Necrosis Factor Alpha (TNFα), Interleukin One (IL-1β), and Interleukin Six (IL-6).
Phase 4 N=48 Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite
Edematous Fibrosclerotic Panniculopathy (EFP) · Cellulite
Primary: Number of Participants by Buttock at Each Level of Bruising on the Investigator Assessment of Bruising Severity Scale at Day 4 — 0; 0; 0; 0 Participants
Phase 3 N=215 Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries
Acute Blunt Soft Tissue Injuries/Contusions
Primary: Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24) — 42.9; 45.5 units on a scale
N/A N=41 Damage Control for Duodenal and Combined Duodenal-Pancreatic Injuries
Injury of Duodenum · Pancreatic Injury
Primary: Duodenal-related Complications — 13; 11; 8; 19 percentage of subjects
N/A N=15 Effects of Different Support Surfaces on the Properties Skin After Loading
Pressure Ulcers
Primary: Transepidermal Water Loss (TEWL) in g/m2/h on Sacrum, at Baseline — 7.8; 7.7; 7.1 g/m2/h
N/A N=60 Heat Versus Ice in the Acute Management of Neck and Back Strain Injuries
Back Strain · Neck Strain
Primary: Pain Score After Treatment — 66; 64 mm
N/A N=20 ICG Fluorescence Imaging in Trauma Patients
Trauma Injury
Primary: Percent of Patients That Complete the Protocol — 61.5; 83.3; 0 percentage of completed patients
N/A N=80 Treatment of Pressure Ulcers Using Biological Skin Substitutes
Pressure Sore
Primary: Percent Change in Wound Area — -78.5; -65.1 percentage change
N/A N=20 Broad Band Light for the Treatment and Prevention of Senile Purpura
Senile Purpura · Bateman's Purpura
Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions
N/A N=120 Neurocognitive Evaluation of Mild Traumatic Brain Injury in the Hospitalized Pediatric Population
Mild Traumatic Brain Injury · Concussion
Primary: The Feasibility of Inpatient Bedside Neurocognitive Testing of Pediatric Patients With Minor Traumatic Brain Injury. — 120 participants
N/A N=16 Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising
Ecchymosis
Primary: Average Bruise Change — -3.68; -3.71; -3.88; -4.13 Units on a Scale
N/A N=53 LED Therapy for the Treatment of Concussive Brain Injury
Brain Concussion
Primary: Mean Difference in Change in Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) Score at Baseline and 6 Weeks. — -0.9; -5.78; 3.52; -7.26 Units on a scale
Phase 3 N=199 Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
Hemorrhagic Shock · Acute Blood Loss Anemia · Traumatic Brain Injury
Primary: Packed Red Blood Cells Equivalents Units Transfused (1 Whole Blood Unit Treated as 1 Packed Red Blood Cell Unit and 1 Fresh Frozen Plasma Unit) — 3.8; 5.7 units
Phase 4 N=20 Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands
Purpura
Primary: Reduction of Bruising — 3.74; 4.50 cm squared
N/A N=420 Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections
Abscess
Primary: Sensitivity and Specificity of Bedside Emergency Ultrasound When Added to the Clinical Examination Compared With Clinical Examination Alone. — 94.7; 93.1; 84.2; 81.4…
Phase 4 N=27 tSCI Contrast Enhanced Ultrasound Study
Acute Spinal Cord Injury
Primary: Feasibility of Intraoperative Contrast-enhanced Ultrasound in Acute Traumatic Spinal Cord Injury - Number of Participants With Successful Intraoperative…